Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 2/20 | 0.74 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.74 |
| ▸ | GSK3B | P49841 | 2/20 | 0.74 |
| ▸ | JAK2 | O60674 | 1/20 | 0.74 |
| ▸ | MET | P08581 | 1/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
| ▸ | PRKACA | P17612 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.74 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.74 |
| ▸ | MST1R | Q04912 | 1/20 | 0.74 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.74 |
| ▸ | PARP1 | P09874 | 3/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.68 |
| ▸ | F7 | P08709 | 1/20 | 0.68 |
| ▸ | F3 | P13726 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601999 | 0.85 | PARP10 (0.60) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL9477764 | 0.84 | NTRK1 (0.59) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL793493 | 0.81 | PARP10 (1.00) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL29676942 | 0.81 | PARP10 (1.00) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL19838574 | 0.78 | PARP10 (0.81) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL31743097 | 0.78 | PARP10 (0.81) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL1438328 | 0.78 | TDP2 (0.59) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL30765133 | 0.78 | TDP2 (0.59) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL31039236 | 0.77 | NTRK2 (0.58) | NTRK2NTRK3NTRK1FLT3GSK3B | |
| SCHEMBL1233219 | 0.76 | NTRK2 (0.56) | NTRK2NTRK3NTRK1FLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200392131-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. | 2020-12-17 | — | — | US | disclosed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2017121674-A1 | HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-07-20 | — | — | WO | disclosed |
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2307365-B1 | SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| US-5362738-A | Used to treat muscle tension, stress, insomnia, anxiety or convulsions | HOFFMANN-LA ROCHE INC. (US) | 1994-11-08 | — | — | US | disclosed |
| US-5258387-A | Controlling muscle tension, stress, insomnia, anxiety or convulsions | HOFFMANN-LA ROCHE INC. (US) | 1993-11-02 | — | — | US | disclosed |
| US-5254578-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1993-10-19 | — | — | US | disclosed |
| US-5143912-A | Muscle relaxants, anticonvulsants, anxiolytic agents | HOFFMANN-LA ROCHE, INC. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0472166-A1 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| EP-0006587-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | disclosed |
| EP-0006587-A1 | Sulfonyl ureas, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392131-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | NTRK2 3966/4885NTRK3 3200/4885NTRK1 2995/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | NTRK2 1235/4885NTRK3 1415/4885NTRK1 1073/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | NTRK2 1235/4885NTRK3 1415/4885NTRK1 1073/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | NTRK2 817/4885NTRK3 571/4885NTRK1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.